CJ 30044Alternative Names: CJ-30044
Latest Information Update: 01 Apr 2016
Price : $50 *
At a glance
- Originator CJ Cheiljedang Corp.
- Mechanism of Action
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Unspecified
Most Recent Events
- 01 May 2013 CJ Cheiljedang Corp. completes a phase I trial in Healthy volunteers in South Korea (NCT01925313)
- 01 Dec 2012 Phase-I clinical trials in Undefined indication (in volunteers) in South Korea (PO)